Reversible Control of Native GluN2B-Containing NMDA Receptors with Visible Light.

Chloé Geoffroy1, Romain Berraud-Pache2, Nicolas Chéron3

  • 1Institut de Biologie de l'Ecole Normale Supérieure (IBENS), Ecole Normale Supérieure, CNRS, INSERM, Université PSL, Paris F-75005, France.

ACS Chemical Neuroscience
|September 6, 2024
PubMed
Summary

Researchers developed OptoNAM-3, a novel light-activated drug that precisely controls NMDA receptors (NMDARs). This tool allows reversible inhibition of GluN2B-NMDARs using visible light for studying brain function.